A
B
Figure S1 A B
Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications C D
Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications E F
Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications G H
Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications
Figure S2 A B
Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications
C
Share No Share 1 or more Indications Indications
Figure S3 A B
Share No Share 1 or more Share No Share 1 or more Indications Indications Indications Indications
C
Share No Share 1 or more Indications Indications
Figure S4 A
Share No Share 1 or more Indications Indications
Figure S5 A Precision−Recall − P: 23840, N: 1299623 1.0 0.8 0.6
CATNIP AUPRC = 0.189
Precision Random AUPRC = 0.0184
0.4 AUPRC = 0.189 AUPRC Rand = 0.0184 0.2 0.0
0.0 0.2 0.4 0.6 0.8 1.0
Recall
Figure S6 Mental Disorder Skin Cancer Lung Cancer A B C
Percent of Drugs in Percent of Drugs in Percent of Drugs in Class Approved for Class Approved for Class Approved for Indication Indication Indication
Location Shift Location Shift Location Shift
Breast Cancer Thryoid Cancer Large Intestine Cancer D E F
Percent of Drugs in Percent of Drugs in Percent of Drugs in Class Approved for Class Approved for Class Approved for Indication Indication Indication
Location Shift Location Shift Location Shift
Upper Aerodigestive tract Cancer Gastric Cancer Renal Cancer G H I
Percent of Drugs in Class Approved for Percent of Drugs in Percent of Drugs in Indication Class Approved for Class Approved for Indication Indication
Location Shift Location Shift Location Shift
Figure S7 Urinary Tract Cancer Endometrium Cancer A B Pleura Cancer C
Percent of Drugs in Percent of Drugs in Class Approved for Percent of Drugs in Class Approved for Indication Class Approved for Indication Indication
Location Shift Location Shift Location Shift
Ovarian Cancer Bone Cancer D E Pancreatic Cancer F
Percent of Drugs in Percent of Drugs in Percent of Drugs in Class Approved for Class Approved for Class Approved for Indication Indication Indication
Location Shift Location Shift Location Shift
Oesophagus Cancer Lymphoma/Leukemia Autonomic Ganglia Cancer G H I
Percent of Drugs in Percent of Drugs in Class Approved for Percent of Drugs in Class Approved for Indication Class Approved for Indication Indication
Location Shift Location Shift Location Shift
Figure S8 A
Drug Pair Types
Kinase Inhibitor & Drug approved for disease
Kinase Inhibitor & Drug not approved for disease
A
Drug Pair Types
Dopamine Antagonist & Drug approved for disease
Dopamine Antagonist & Drug not approved for disease
Figure S9 A
Benzatropine & Trimipramine
Rotigotine & Trimipramine
CATNIP Score CATNIP Di erence in Di erence
Figure S10 A 20 B
6
15
4
10 Overlap of Shared kegg Overlap Overlap of Shared reactome Overlap
2
5
0 0
METIXENE ● ● ● BENZATROPINE ● ●
BENZATROPINE ● ● ● ATROPINE ● ●
ATROPINE ● ● ● ● METIXENE ● ●
PERGOLIDE ● ● ● PERGOLIDE ● ●
AMITRIPTYLINE ● ● ● ● ● ● ● AMITRIPTYLINE ● ● ● ●
40 30 20 10 0 9 6 3 0 Set Size Set Size
C D
40
15
30
10
20 Overlap of Shared mf Overlap Overlap of Shared reactome Overlap
5 10
0 0
METIXENE ● ● ● ●
GLICLAZIDE ● PERGOLIDE ● ● ● ● ●
ATROPINE ● ● ● ● ● ● ●
BENZATROPINE ● ● ● ● ● VANDETANIB ● ●
AMITRIPTYLINE ● ● ● ● ● ● ● ● ● ● ●
100 75 50 25 0 20 15 10 5 0 Set Size Set Size
E F 30
15
20
10 Overlap of Shared mf Overlap Overlap of Shared kegg Overlap
10 5
0 0
GLICLAZIDE ● GLICLAZIDE ●
VANDETANIB ● ● VANDETANIB ● ●
25 20 15 10 5 0 40 20 0 Set Size Set Size
Figure S10 Table S1 Table S2